Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Goodman

Podiatrist Glenview, IL Doctor of Podiatric Medicine

NPI 1295781433 CMS profile 970235

2401 Ravine Way Ste 200, Glenview, IL 60025

Open in the dashboard

General payments

$12,754

190 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Goodman of Glenview, IL is reported in the CMS Open Payments database as having received $12,754 across 190 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Podiatrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,132 33
2024 General $5,498 45
2023 General $2,036 33
2022 General $1,529 24
2021 General $248 6
2020 General $1,242 22
2019 General $1,069 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Goodman
  • Podiatrist median
  • Middle half of Podiatrist
  • National median

In program year 2025, general payments to Paul Goodman were reported at $1,132. Among 4,572 Podiatrist profiles paid that year, the median was $260 and the middle half received between $94 and $777.

Show as a table
Year Paul Goodman Podiatrist median Middle half National median
2019 $1,069 $196 $72–$601 $163
2020 $1,242 $118 $38–$335 $114
2021 $248 $169 $57–$573 $132
2022 $1,529 $220 $74–$782 $149
2023 $2,036 $208 $71–$635 $160
2024 $5,498 $237 $87–$681 $164
2025 $1,132 $260 $94–$777 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Fusion Orthopedics USA, LLC $4,144 11 payments
  2. Smith+Nephew, Inc. $1,331 17 payments
  3. Zimmer Biomet Holdings, Inc. $1,048 19 payments
  4. Treace Medical Concepts, Inc. $1,006 32 payments
  5. Stryker Corporation $691 17 payments
  6. Wright Medical Technology, Inc. $522 11 payments
  7. Medartis Inc. $465 6 payments
  8. Acera Surgical, Inc. $401 12 payments
  9. Nextremity Solutions Inc. $391 5 payments
  10. Trice Medical, Inc. $373 5 payments
  11. Other $2,383 55 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,119 181 payments
  2. Consulting Fee $3,600 3 payments
  3. Travel and Lodging $1,035 6 payments
Products named General payments · program years 2019–2025
  1. LAPIPLASTY SYSTEM $871 24 payments
  2. FOOTPRINT $596 3 payments
  3. Bone Anchors with Arthroscopic Delivery System $596 3 payments
  4. APTUS $465 6 payments
  5. MOTOBAND $383 6 payments
  6. CERAMENTBONE VOID FILLER $365 7 payments
  7. CERAMENT G $365 7 payments
  8. EVOS MINI $357 4 payments
  9. Lapidus Plate $290 6 payments
  10. Stratum Foot Plating System $260 5 payments
  11. Other $4,911 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

351

Median for Podiatry: 160

Drug cost

$3,121

Median for Podiatry: $2,368

Branded share of claims

10.5%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 64 $788
Methylprednisolone Generic 66 $425
Colchicine Generic 17 $319
Minocycline Hcl Generic 12 $281
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 37 $277
Clindamycin Hcl Generic 15 $219
Hydromorphone Hcl Generic 58 $209
Cefadroxil Generic 22 $208
Doxycycline Hyclate Generic 22 $148
Ciprofloxacin Hcl Generic 14 $146

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 83 billing codes

Paid by Medicare

$202,814

Of which drugs: $320

Medicare patients

623

Average age 76

Services billed

2,801

394 women, 229 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 65%
Osteoporosis 29%
Diabetes 26%
Ischemic heart disease 24%
Chronic kidney disease 22%
Depression 20%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 46 59 $320

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

190 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record